z-logo
Premium
The risk of cardiac complications following noncardiac surgery in patients with drug eluting stents implanted at least six months before surgery
Author(s) -
Assali Abid,
VakninAssa Hana,
Lev Eli,
Bental Tamir,
BenDor Itsik,
Teplitsky Igal,
Brosh David,
Fuchs Shmuel,
Eidelman Leonid,
Battler Alexander,
Kornowski Ran
Publication year - 2009
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.22158
Subject(s) - medicine , perioperative , myocardial infarction , surgery , thrombosis , cardiac surgery , stent , cardiology
Aims : Given the anecdotal reports and case series suggesting that drug‐eluting coronary stents [DES] may be still vulnerable to coronary thrombosis after six months, we sought to assess this risk in patients undergoing non‐cardiac surgery six months after stenting. Methods and Results : Linking the Rabin Medical Centre interventional cardiology database with its non‐cardiac surgical database, we identified 78 patients who underwent DES placement and subsequently [after six months] had noncardiac surgery [15‐vascular, 37‐ abdominal and genitourinary and 26‐others, excluding ophthalmic surgery]. Outcome measures included 30‐day rate of postoperative myocardial infarction (MI), DES‐related thrombosis, and cardiac mortality. Major adverse cardiac events [death and non‐fatal MI] occurred in 6 (7.7%) patients including 2 cardiac deaths (2.6%), 4 (5.1%) non‐fatal myocardial infarctions (MIs). Two patients (2.6%) sustained stent thrombosis [one patient had ‘definite’ and one ‘probable’ stent thrombosis]. All MIs [including stent thrombosis] occurred in the vascular and abdominal surgery group. Two of the MIs events occurred while the patients were on dual antiplatelet agents. In conclusions : Perioperative cardiac events during non cardiac surgery after six months of DES deployment still occur. These cardiac complications [not entirely prevented by continued dual antiplatelet agents] remain a matter of diagnostic and therapeutic challenge and concern. © 2009 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom